T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System by Huang, W-C et al.
of May 31, 2017.
This information is current as
System
Ligands for the NKG2D Stress Surveillance 
T Cells Infiltrating Diseased Liver Express
Dimitra Peppa and Mala K. Maini
Giuseppe Fusai, Antoine Toubert, Patrick T. Kennedy, 
Rosenberg,John Trowsdale, Brian R. Davidson, William M. 
Chang,S. Gill, Harsimran Singh, Francis Robertson, Chiwen 
Wei-Chen Huang, Nicholas J. Easom, Xin-Zi Tang, Upkar
http://www.jimmunol.org/content/198/3/1172
doi: 10.4049/jimmunol.1601313
December 2016;
2017; 198:1172-1182; Prepublished online 28J Immunol 
Material
Supplementary
3.DCSupplemental
http://www.jimmunol.org/content/suppl/2016/12/28/jimmunol.160131
References
http://www.jimmunol.org/content/198/3/1172.full#ref-list-1
, 24 of which you can access for free at: cites 61 articlesThis article 
Subscription
http://jimmunol.org/subscription
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/About/Publications/JI/copyright.html
Submit copyright permission requests at: 
Email Alerts
http://jimmunol.org/alerts
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Copyright © 2017 The Authors All rights reserved.
1451 Rockville Pike, Suite 650, Rockville, MD 20852
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology
 by guest on M
ay 31, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
 by guest on M
ay 31, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
The Journal of Immunology
T Cells Infiltrating Diseased Liver Express Ligands for the
NKG2D Stress Surveillance System
Wei-Chen Huang,*,† Nicholas J. Easom,* Xin-Zi Tang,* Upkar S. Gill,‡ Harsimran Singh,*,x
Francis Robertson,{ Chiwen Chang,‖ John Trowsdale,‖ Brian R. Davidson,x,{
William M. Rosenberg,x Giuseppe Fusai,x,{ Antoine Toubert,# Patrick T. Kennedy,‡
Dimitra Peppa,*,1 and Mala K. Maini*,1
NK cells, which are highly enriched in the liver, are potent regulators of antiviral T cells and immunopathology in persistent viral
infection. We investigated the role of the NKG2D axis in T cell/NK cell interactions in hepatitis B. Activated and hepatitis B virus
(HBV)–specific T cells, particularly the CD4 fraction, expressed NKG2D ligands (NKG2DL), which were not found on T cells
from healthy controls (p < 0.001). NKG2DL-expressing T cells were strikingly enriched within HBV-infected livers compared with
the periphery or to healthy livers (p < 0.001). NKG2D+NK cells were also increased and preferentially activated in the HBV-
infected liver (p < 0.001), in direct proportion to the percentage of MICA/B-expressing CD4 T cells colocated within freshly
isolated liver tissue (p < 0.001). This suggests that NKG2DL induced on T cells within a diseased organ can calibrate NKG2D-
dependent activation of local NK cells; furthermore, NKG2D blockade could rescue HBV-specific and MICA/B-expressing T cells
from HBV-infected livers. To our knowledge, this is the first ex vivo demonstration that non-virally infected human T cells can
express NKG2DL, with implications for stress surveillance by the large number of NKG2D-expressing NK cells sequestered in the
liver. The Journal of Immunology, 2017, 198: 1172–1182.
N
atural killer cells are well known for their capacity to kill
virally infected and transformed cells, but also have
potent regulatory capacity (1–3). In particular, their
ability to modulate antiviral T cell responses, thereby regulating
immunity and immunopathology, has been highlighted by several
studies in murine CMVand lymphocytic choriomeningitis virus (4–
9). We demonstrated the relevance of this in humans with persistent
hepatitis B virus (HBV) infection, where NK cells were able to
delete HBV-specific CD8 T cells in a rapid, contact-dependent
manner (10). More recently, HBV-specific CD4 T cells have also
been shown to be susceptible to NK regulation in patients with
HBV suppressed by antivirals (11). We postulated that interactions
between NK cells and T cells would be accentuated in the HBV-
infected liver, where NK cell frequencies are greatly enriched,
T cells are dysregulated, and cell to cell contact is facilitated by the
narrow-lumen, low flow rate of the liver sinusoidal vasculature.
NK cells are the most prevalent lymphocyte population in the
human liver, accounting for up to a third of intrahepatic leukocytes
(12, 13). In addition to conventional bone marrow–derived NK cells,
recent studies in mice have defined a specialized hepatic-specific
lineage of NK cells (14–17), underscoring their relevance in the
liver. Similarly, we have recently described a large subset of CXCR6+
TbetloEomeshi NK cells residing in human liver that are not present
in the circulation (18). In viral hepatitis, NK cells (particularly the
liver-resident subset) upregulate TRAIL, barely expressed on healthy
hepatic NK cells in humans, and can kill HBV/hepatitis C virus–
infected hepatocytes bearing TRAIL death receptors (18–21). The
TRAIL pathway also contributes to the capacity of NK cells to
preferentially kill T cells directed against HBV and those activated
within the HBV-infected liver, which we found express the death-
inducing receptor TRAIL-R2 not normally found on T cells (10).
Although we identified TRAIL as one effector pathway used by NK
cells to delete T cells, the interactions initiating NK killing of T cells
have not been elucidated in humans. We hypothesized that T cells in
the metabolically stressed environment of the HBV-infected liver
may upregulate specific ligands to activate NK cell cytotoxicity.
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We focused on the NKG2D axis because this plays a critical role
in lymphoid stress surveillance within tissues (22–24). The rele-
vance of this pathway was supported by the fact that NK cells
maintain high levels of the major activatory receptor NKG2D in
HBV (25, 26), and NKG2D-dependent killing of T cells has been
demonstrated in vitro (27–31) and in murine models in vivo (4).
Various stressors (oxidative, genotoxic, viral infection) can induce
epithelial cells to express one or more ligands for NKG2D, as a
delicately balanced system for regulating immunopathology (22,
32). Likewise, human T cells have been shown to have inducible
expression of NKG2D ligands (NKG2DL) when exposed to mi-
togens or other stimuli and/or infected with CMV or HIV in vitro
(28, 33–38). To our knowledge, in this study we demonstrate for
the first time the in vivo induction of NKG2DL on uninfected
human T cells, particularly on activated and virus-specific CD4
T cells within the HBV-infected liver milieu. We provide ex vivo
data suggesting that CD4 T cell expression of NKG2DL can drive
local NK cell activation in a dose-dependent manner.
Materials and Methods
Patients and healthy controls
Blood samples were obtained from 113 chronic hepatitis B (CHB) patients
recruited from the Mortimer Market Clinic (Central and North West
London National Health Service Trust), the Royal Free and University
College London hospitals and the Royal London Hospital (Barts Health
National Health Service Trust). A total of 46 healthy control blood samples
were obtained from staff or students at University College London. Surplus
liver tissue was obtained from 36 CHB patients undergoing diagnostic liver
biopsies. Healthy liver remote from the tumor site was obtained from 11
non-HBV infected patients undergoing tumor resection for colorectal
metastases. Nine transplant perfusates from cadaveric donor livers were
collected during liver transplant surgery under the standard graft prepa-
ration protocols. The study was approved by the relevant ethical review
boards and informed consent was obtained in writing. All CHB patients
had detectable hepatitis B surface Ag and DNA for .6 mo, were anti-
hepatitis C virus, anti-d virus and anti-HIV–Ab negative and treatment
naive. Liver inflammation was determined by serum alanine transaminase
(ALT). Details of the clinical characteristics of all HBV patients are in-
cluded in Table I.
PBMC and intrahepatic lymphocyte isolation
PBMC isolated from whole blood by standard gradient centrifugation on
Ficoll-Paque Plus (GE Healthcare). Intrahepatic lymphocytes (IHL) were
obtained following gentle mechanical disruption of liver tissue prior to
passing through a 70 mm cell strainer (BD Biosciences) and multiple
washes with RPMI 1640 (Invitrogen) as previously described (13, 20).
IHLs from transplant perfusates were retrieved by density-gradient
centrifugation.
Flow cytometric analysis and Abs
For phenotypic analysis, PBMC and IHLwerewashed with PBS and stained
with a fixable Live/Dead blue dye (Invitrogen) at 4˚C for 10 min, prior to
Fc receptor blocking with FcR blocking reagent (Miltenyi Biotec, Bergisch
Gladbach, Germany). Surface staining was performed at 4˚C for 30 min in
the presence of saturating concentrations of mAbs, or isotype matched
controls. The following Abs were used for the sequential gating strat-
egy (Supplemental Fig. 1A): CD3-PE-Cy7 (eBioscience), CD4-APC-eFluor780
(eBioscience), CD8-AlexaFluor700 (eBioscience), CD19-APC-eFluor780
(eBioscience), CD56-ECD (Beckman Coulter), HLA-DR-V500 (BD
Biosciences), NKG2D-Alexa Fluor 488 (R&D Systems), MICA/B-PE
(eBioscience), ULBP1-FITC (R&D Systems), ULBP2/5/6-APC (R&D
Systems), and ULBP3-PE (R&D Systems). The frequencies of peptide-
specific CD8 T cells from HLA-A2 positive individuals were evaluated
directly ex vivo by multimer staining as previously described (39). Briefly,
total PBMCs were stained with APC-labeled CMV pp65 495–504 or HBV
core 18–27, envelope 183–191, envelope 335–343, envelope 348–357,
and polymerase 508–510 dextramers (Immudex, Denmark) at 37˚C for
15 min in complete RPMI 1640 plus 10% FCS. The cells were then
washed, pelleted, and stained as above. A control dextramer was used
to identify the population of positive cells. Intracellular staining (ICS)
to assess proliferation was performed using Ki67-FITC (BD Biosci-
ences) mAb directly ex vivo. ICS for IFN-g or active caspase 3 levels was
carried out by using IFN-g V450, (BD Biosciences) or Caspase 3-PE (BD
Biosciences) mAbs in 0.1% saponin for 30 min. All samples were acquired
on a LSR Fortessa or BD LSR II using BD FACSDiva 6.0 (BD Biosciences).
Data were analyzed using FlowJo v.8 (TreeStar, Ashland, OR).
Cell lines
A 2B4 cell line carrying GFP–conjugated NF-AT transfected with the
human NKG2D/DAP10-CD3z complex as previously described (40) was
used to screen for NKG2DL on PBMC. B-lymphoblastoid cell lines, C1R
and C1R transfected with MICA*008 (C1R-MICA) were used as a source
of cell-bound MICA, expressing 0 and 100% cell-bound MICA respec-
tively; anti-CD19 APC-eFluor 780 (eBioscience) was used to identify the
cells and MICA expression was verified by MICA/B mAb staining as
previously described (41).
NK and CD4 T cell isolation
NK cells and CD4 T cells were isolated from PBMC (.95% purity and
viability) (NK isolation kit and CD4 T cell isolation kit respectively;
Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufac-
turer’s instructions.
NKG2DL expression and in vitro stimulation
The presence of NKG2DL on PBMC or isolated CD4 T cells from CHB
patients was investigated in cocultures with GFP reporter cells. Cells were
cocultured with 2B4 transfectants overnight in RPMI 1640 containing 5%
FCS, and GFP expression analyzed by flow cytometry. Purified CD4 T cells
or PBMC from healthy controls were rested for 48 h prior to the addition of
H2O2 solution (30%; BDH Aristar) at varying concentrations (0.25–1 mM)
for 0.5–2 h, followed by surface staining for NKG2DL as described above.
NK cell degranulation
To measure NK cell capacity to degranulate, purified NK cells were
cocultured at 1:1 ratio with target cells (C1R/C1R-MICA) at 37˚C for 6 h, in
the presence of anti-CD107a-APC (BD Biosciences). Brefeldin A (1 mg/ml;
Sigma-Aldrich) and Monensin (1 mg/ml; Sigma-Aldrich) were added after
1 h. Where indicated, an anti-NKG2D blocking Ab or control Ab mAb
(0.5 mg/ml; eBiosciences) was added at the onset of culture. NKG2D
blockade did not affect NK cell viability.
Short-term culture and NKG2D blockade
PBMC were stimulated with HBV overlapping peptides (OLP) (15mer
peptides overlapping by 10 residues spanning genotype D HBV core
protein, 1 mg/ml; JPT) in the presence of 40 IU IL-2 (Miltenyi Biotec) in
RPMI 1640 complete medium for 10 d at 37˚C. IL-2 and medium were
refreshed on day 4 of culture. On day 9, PBMC were restimulated with
1 mg/ml OLP overnight, in the presence of Brefeldin A (1 mg/ml). Virus-
specific T cells were identified via ICS for corresponding IFN-g produc-
tion. To examine the effect of blocking NKG2D on virus specific CD4
T cells, NKG2D blocking (0.5 mg/ml, eBiosciences) or an isotype-matched
control mAb were added with peptide at onset of culture and cells were
treated as described above.
Overnight stimulation
For overnight stimulation of PBMC or IHL, 10 mg/ml HBV OLPs were
added and the cells were incubated at 37˚C in the presence of Brefeldin A
(1 mg/ml) (added after 1 h). HBV-specific T cells were identified by ICS
for IFN-g.
Statistical analysis
The non-parametric Mann–Whitney U test (for two groups), the Wilcoxon
signed rank test (for two paired groups), Kruskal–Wallis (for .2 non-
paired groups) or Friedman (for .2 paired groups) one-way tests were
used as appropriate. Correlations between variables were analyzed using
Spearman’s rank correlation coefficient (r). A p value , 0.05 was
considered significant for all tests. All figures are marked as follows:
*p , 0.05, **p , 0.005, ***p , 0.001.
Results
Induction of NKG2DL on T cells in CHB
The expression of NKG2DL is low in healthy tissues, but can be
induced by cellular stress such as infection, inflammation, or tumor
The Journal of Immunology 1173
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transformation (22, 32). We hypothesized that NKG2DL may be
upregulated on T cells in CHB, allowing them to interact with
NKG2D+NK cells in the HBV-infected liver. To investigate
NKG2DL expression, CD4 and CD8 T cells from healthy controls
and a well-characterized cohort of patients with CHB (Table I) were
evaluated by flow cytometry (Supplemental Fig. 1A) using a panel
of mAbs specific for MICA/B, ULBP1, ULBP2/5/6, and ULBP3.
Out of this panel of ligands, MICA/B was not detectable on T cells
from controls but showed subtle but significant induction on pe-
ripheral CD4 and CD8 T cells in patients with CHB; T cell
MICA/B levels did not correlate with virological parameters but
were more increased in those with more pronounced liver inflam-
mation (serum ALT .60 IU/l, Fig. 1A, 1B). MICA/B was prefer-
entially expressed on CD4 compared with CD8 T cells (Fig. 1C).
ULBP1 was also selectively elevated on CD4 T cells from patients
with HBV-related liver inflammation (serum ALT .60 IU/l, Fig.
1D). However, no significant changes were observed for the T cell
expression of the remaining NKG2DL (ULBP2/5/6 and ULBP3) in
CHB (data not shown). As a further readout, we screened with a
reporter cell line expressing NKG2D tagged to GFP and able to
bind all NKG2DL, again confirming that their levels were selec-
tively enriched in patients with HBV-related liver inflammation
(Supplemental Fig. 1B).
Although NKG2DL were consistently increased on T cells from
patients with CHB, the percentage of expressing cells in the pe-
ripheral circulation was low, suggesting that a subset of T cells was
selectively affected. We hypothesized that NKG2DL might be
preferentially induced on those T cells activated by the HBV-
infected liver milieu. Using direct ex vivo staining, we found an
enrichment of MICA/B expression on the circulating, activated
(HLA-DR+) fraction compared with HLA-DR2 T cells, particu-
larly in the CD4 compartment (Fig. 1E).
Previous reports have shown upregulation of NKG2DL fol-
lowing in vitro induction of T cell proliferation (28). However, a
simple relationship between antigenic proliferation and NKG2DL
induction was not supported by our findings; there was no ex vivo
correlation with viral load and no increase in proliferating (Ki67+)
T cells within the NKG2DL-expressing fraction (Supplemental
Fig. 1C). Reactive oxygen species, leading to oxidative stress,
have also been shown to induce NKG2DL on cell lines (28, 42) and
DNAM-1 ligand on T cells (43), and are known to be elevated in the
liver in HBV-related pathology (44, 45). A possible role for oxi-
dative stress in CHB was supported by the fact that in vitro expo-
sure to H2O2 recapitulated the pattern of induction of NKG2DL
seen on T cells from patients. Following 1 h exposure to H2O2,
MICA/B was consistently induced on purified CD4 T cells from 14
healthy controls (Supplemental Fig. 1D) and to a lesser extent on
CD4 T cells within PBMC (Supplemental Fig. 1E). The H2O2-
induced upregulation of NKG2DL on CD4 within PBMC was
most striking for MICA/B and ULBP-1 (Supplemental Fig. 1E,
1F), mimicking the preferential increase of these ligands in our
ex vivo studies of CHB patients. By contrast, in vitro exposure
to a large variety of other factors relevant to the liver milieu
(TNF-a, IFN-g, IFN-a, IL-8, IL-2, IL-15, IL-17, IL-10, TGF-b,
EGF, L-arginine depleted medium, hypoxic incubation, LPS,
and HBV viral Ags) failed to reproducibly induce NKG2DL on
T cells (data not shown).
T cells infiltrating HBV-infected livers are enriched for
NKG2DL
To probe T cell NKG2DL expression at the site of disease path-
ogenesis, we isolated IHL from surplus liver biopsy tissue from 21
patients with CHB and compared these with their paired PBMC
samples. IHL from 20 non-HBV infected control livers were used Ta
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FIGURE 1. NKG2DL induction on activated T cells in patients with CHB. Representative FACS plots gated on live CD3+ (A) and summary data (B) of
ex vivo MICA/B expression on global CD4 and CD8 T cells from healthy controls (n = 9), CHB patients with ALT#60 IU/l (n = 13) or ALT.60 IU/l (n = 14),
analyzed by Kruskal–Wallis test (gates set using isotype controls). (C) Comparison of MICA/B expression on peripheral CD4 and CD8 T cells from CHB
patients (n = 27), analyzed by Wilcoxon signed rank test. (D) Summary results of ex vivo ULBP1 mAb staining of global CD4 T cells from healthy controls
(n = 11), CHB patients with ALT #60 IU/l (n = 16) or ALT .60 IU/l (n = 9), analyzed by Kruskal–Wallis test. (E) Representative FACS plots (gated on
live CD3+) and summary data of MICA/B staining of HLA-DR2 and HLA-DR+ CD4 and CD8 T cells from the periphery (n = 22) of patients with CHB,
analyzed by Wilcoxon signed rank test. *p , 0.05, **p , 0.005, ***p , 0.001.
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for comparison (isolated from either healthy livers, obtained during
resection of colorectal metastases, or from transplant perfusates
from cadaveric donor livers). We observed a striking increase in the
proportion of T cells expressing MICA/B directly ex vivo from the
liver compared with the periphery of patients with CHB. By
contrast, intrahepatic T cells from control livers had low expression
of MICA/B (Fig. 2A, 2B). The percentage of intrahepatic CD4
T cells expressing MICA/B in HBV-infected livers could be as
high as 18%, a more than 10-fold increase of the maximum seen
on circulating CD4 in CHB, or on intrahepatic CD4 of healthy
livers (Fig. 2A, 2B). In the liver of patients with CHB, as in their
circulation, MICA/B was preferentially expressed on CD4 com-
pared with CD8 T cells (Fig. 2C) and on the activated fraction
(HLA-DR+ versus HLA-DR2 CD4 and CD8, Fig. 2D). Within the
activated (HLA-DR+) fraction, MICA/B was expressed on more
CD4 than CD8 T cells and on more intrahepatic than peripheral
T cells (Fig. 2E), consistent with the concept that factors in the
HBV-infected liver environment could be driving upregulation
of NKG2DL.
Increased NKG2DL on HBV-specific T cells
We next investigated whether HBV-specific T cells can prefer-
entially upregulate NKG2DL. HBV-specific T cells were identified
by IFN-g production following in vitro stimulation and short-term
expansion with OLP spanning the HBV core protein. After stim-
ulation of PBMC, HBV-specific CD4 and CD8 T cells expressed
MICA/B at higher levels than IFN-g2 T cells (Fig. 3A). Ex vivo
examination using a panel of HLA-A2/peptide dextramers (with-
out any in vitro stimulation) likewise showed increased MICA/B
on HBV-specific T cells compared with global T cells or com-
pared with CMV-specific T cells within the same donors (Fig. 3B,
Supplemental Fig. 2A).
We postulated that intrahepatic HBV-specific T cells, having
recently encountered their cognate Ag within the liver-specific
milieu, would be more likely to have upregulated the stress ligand
MICA/B. In support of this, intrahepatic HBV-specific CD4 and CD8
T cells were considerably enriched for MICA/B expression after
overnight culture with their cognate peptide (Fig. 3C). Intra-
hepatic T cells responding to HBV peptides showed greater in-
duction of MICA/B than their circulating counterparts, with up
to 94% of intrahepatic HBV-specific CD4 expressing MICA/B
(Fig. 3C, 3D).
HBV-specific and MICA/B-expressing T cells can be
reconstituted upon NKG2D blockade
To test whether the expression of NKG2DL rendered HBV-specific
T cells susceptible to deletion by NK cells, we analyzed their
recovery upon the removal/addition of NK cells with or without
NKG2D blockade. HBV-specific CD4 T cells could be increased
by NK cell depletion, eliminated by their readdition and protected
by the addition of NKG2D-blocking mAbs (Fig. 4A). The ca-
pacity of HBV-specific CD4 T cells to be boosted by NK depletion
or NKG2D blockade and reduced by NK cell addition is sum-
marized for 15 patients with CHB in Fig. 4B. NKG2D-mediated
reconstitution was only significant in patients with HBV-related
liver inflammation (ALT .60 IU/l, Fig. 4C), in keeping with the
increased NKG2DL observed we had observed in this group.
NKG2D blockade was unable to mediate any additional restora-
tion of HBV-specific CD4 T cells once PBMC were depleted of
NK cells (compared with NK depletion without NKG2D block-
ade, Supplemental Fig. 2B), demonstrating that NK cells were
required for the NKG2D-dependent killing of HBV-specific CD4
T cells.
NKG2D blockade also recovered HBV-specific CD4 but not
CD8 T cells within liver-infiltrating lymphocytes (Fig. 4D, 4E),
with more restoration achievable from liver lymphocytes than
their circulating counterparts (Fig. 4F). In support of this deletion
being partially triggered by recognition of the high levels of the
NKG2DL MICA/B on HBV-specific T cells, we found that liver-
infiltrating CD4 T cells expressing MICA/B+ were increased
following NKG2D blockade (Fig. 4G, 4H).
CD4 T cell NKG2DL induction correlates with enhanced
activation of NKG2D+NK cells in the HBV-infected liver
To investigate the interaction of NKG2DL-expressing T cells with NK
cells, we first examined if NK cells in the same HBV-infected livers
maintainedNKG2D expression. Although downregulation of NKG2D
has been reported in some situations of pathologic overstimulation
(46–48), we found no evidence for this in CHB. Both peripheral and
intrahepatic NK cells from patients with CHB maintained a com-
parable level of NKG2D to those from non-HBV infected controls
(Fig. 5A, 5B). Unexpectedly, analysis of paired samples revealed that
NKG2D was even more highly expressed on intrahepatic (mean 86%
NKG2D+NK cells and increased mean fluorescence intensity) than
peripheral NK cells in CHB, and was at a similarly high level on NK
cells in healthy livers (Fig. 5A, 5B, Supplemental Fig. 3A).
We then compared the activation status of peripheral and
intrahepatic NKG2D IFN-g–expressing NK cells from patients
with CHB to those from healthy controls (healthy liver from re-
sections for metastases or transplant perfusates of deceased donor
livers). The NKG2D+ fraction of peripheral NK cells was more
activated (HLA-DR+) in CHB than healthy donors (Fig. 5C).
NKG2D+NK cells in HBV-infected livers showed a further highly
significant increase in activation measured directly ex vivo by
HLA-DR expression, compared with either their circulating
counterparts or the NK cells within non–HBV-infected control
livers (Fig. 5A, 5C).
To test our hypothesis that increased HLA-DR expression by
NKG2D+NK cells in the HBV-infected liver could reflect activation
by NKG2DL-expressing cells, we initially employed an in vitro
system. A lymphoblastoid cell line transfected with MICA*008
(C1R-MICA, expressing 98.5% MICA+, Supplemental Fig. 3B) or a
control cell line lacking MICA (C1R) were cocultured for 6 h with
NK cells from controls or patients with CHB. MICA-expressing
target cells could trigger increases in activation (HLA-DR) and
degranulation (CD107) of NKG2D+NK cells from healthy con-
trols and patients with CHB (Supplemental Fig. 3C), with the
MICA-stimulated increase in degranulation greater for NK cells
from patients with CHB (Supplemental Fig. 3D). Mixtures of the
C1R-MICA and C1R-control cell line at varying ratios showed a
clear dose-response of NK cells from patients with CHB to
MICA-induced activation (HLA-DR) and degranulation (CD107)
(Supplemental Fig. 3E, 3F). Levels of MICA expression analo-
gous to those noted on patient T cells were able to increase the
percentage of HLA-DR–expressing NK cells in the same range as
observed in patient samples (Supplemental Fig. 3E).
To further probe the link between NKG2DL-expressing T cells
and NK cell activation, we quantitated these two parameters in
parallel using direct ex vivo analysis of blood and liver biopsy
tissue from 20 patients with CHB. A highly significant correlation
between the percentage of CD4 T cells expressingMICA/B and the
proportion of activated (HLA-DR+) NKG2D+NK cells was seen in
the periphery, and even more robustly within the liver (r = 0.72,
p = 0.0003, Fig. 5D, 5E). No such correlation was found with
MICA/B on CD8 T cells (data not shown).
Taken together, our analysis of tissue samples from the site of
HBV pathogenesis revealed enhanced NKG2D expression and
1176 NKG2D PATHWAY INDUCTION IN HEPATITIS B
 by guest on M
ay 31, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
selective activation of NKG2D-expressing NK cells, in association
with induction of NKG2DL on liver-infiltrating CD4 T cells. Their
close ex vivo correlations suggest NKG2DL-expressing CD4
T cells may be able to calibrate NK cell activation.
Discussion
To our knowledge, in this study we provide the first direct ex vivo
evidence that uninfected human T cells are capable of expressing
selective NKG2DL, and suggest that this allows them to engage in
FIGURE 2. Enrichment of NKG2DL-expressing T cells within HBV-infected but not healthy liver. Representative FACS plots gated on live CD3+ (A) and
summary (B) of ex vivo MICA/B expression on paired peripheral and intrahepatic T cells from CHB patients (n = 27), and intrahepatic T cells from non-HBV
infected controls (intrahepatic lymphocytes isolated from healthy liver resected distant to colorectal metastases [filled triangles n = 11] or from transplant
perfusates of deceased donor livers [open triangles n = 9]; analyzed by Kruskal–Wallis test). (C) Comparison of MICA/B expression on intrahepatic CD4 and
CD8 T cells from CHB patients (n = 27), analyzed by Wilcoxon signed rank test. (D) Representative FACS plots (gated on live CD3+) and summary data of
MICA/B staining of HLA-DR2 and HLA-DR+ CD4 and CD8 T cells from the liver (IHL n = 21) of patients with CHB, analyzed by Wilcoxon signed rank test.
(E) Comparison of ex vivo MICA/B expression on HLA-DR+ CD4 and CD8 T cells from the PBMC (n = 22) and liver (n = 21) of CHB patients, analyzed by
Mann–Whitney U test (comparison between CD4 and CD8 T cells in same donors by Wilcoxon signed rank test). ***p , 0.001.
The Journal of Immunology 1177
 by guest on M
ay 31, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
cross-talk with NKG2D-expressing NK cells. We demonstrate
that the NKG2DL MICA/B is preferentially expressed on acti-
vated and HBV-specific CD4 T cells, particularly those within
the HBV-infected liver. NKG2D expression is increased on NK
cells from the HBV-infected liver and their enhanced activation
correlates with the proportion of intrahepatic CD4 T cells
expressing MICA/B. Our data reveal the novel paradigm of
NKG2DL-expressing T cells sequestered in diseased livers; this
raises the possibility that they will be enriched among tissue-
resident populations, and contribute to organ-specific pathogene-
sis in other settings.
There are eight different NKG2DL in humans, which also
exhibit high allelic polymorphism, providing an intricate sys-
tem for signaling cellular stress and fine-tuning the response of
FIGURE 3. NKG2DL expression on HBV-specific T cells. Representative FACS plots (gated on live CD3+) and summary data of MICA/B staining of
HBV-specific (IFN-g+ following stimulation with OLP spanning HBV core) and IFN-g2 CD4 and CD8 T cells of patients with CHB from (A) periphery
after 10 d culture (n = 17) and (C) liver after overnight culture (n = 12), analyzed by Wilcoxon signed rank test. (B) Comparison of MICA/B expression on
global, HBV/dextramer-stained and CMV/dextramer-stained ex vivo peripheral CD8 T cells from patients with CHB (n = 19, of which nine were CMV
responders), analyzed by Kruskal–Wallis test. (D) Summary results of MICA/B expression on HBV-specific (IFN-g+) CD4 and CD8 T cells from paired
PBMC (n = 10) and IHL (n = 12 of which 10 were paired samples) following overnight HBV OLP stimulation, analyzed by Wilcoxon rank test. **p ,
0.005, ***p , 0.001.
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NKG2D-bearing cells (22). We observed preferential upregu-
lation of the ligands MICA/B and ULBP-1 on T cells from pa-
tients with CHB. By contrast, the HIV protein Vpr has been
shown to selectively induce ULBP-2 on mitogen–activated HIV-
infected CD4 T cells (49). The expression of particular NKG2DL
on infected cells is specifically counter-regulated by a number of
viral proteins in CMV or HIV infection, underscoring the im-
portance of these signals for alerting the immune system (33, 36–38,
FIGURE 4. Impact of NK cells and NKG2D blockade on HBV-specific and MICA/B-expressing T cells. Representative FACS plots (A) of HBV-specific
(IFN-g+) CD4 T cell changes upon NK cell depletion, NK cell readding +/2 NKG2D blockade following short-term culture of PBMC from patients with
CHB with HBV OLP. (B) Summary data of HBV-specific (IFN-g+) CD4 T cell changes upon NK-depletion, NK cell readding and NKG2D blockade
following short-term culture with HBV OLP in PBMC from patients with ALT .60 IU/l (n = 15), analyzed by Friedman test. (C) Comparison of HBV-
specific (IFN-g+) CD4 T cell restoration upon NKG2D blockade following short-term culture with HBV OLP of PBMC from patients with ALT #60 IU/l
(n = 11) and patients with ALT .60 IU/l (n = 15), analyzed by Wilcoxon signed rank test. Representative FACS plots (D) and summary data (E) of
intrahepatic HBV-specific (IFN-g+) CD4 and CD8 T cell changes upon NKG2D blockade following overnight HBV OLP stimulation in IHL from patients
with CHB (n = 12), analyzed by Wilcoxon signed rank test. (F) Comparison of HBV-specific (IFN-g+) CD4 T cell restoration upon NKG2D blockade
following overnight HBV OLP stimulation in paired PBMC and IHL from patients with CHB (n = 9), analyzed by Wilcoxon signed rank test. Repre-
sentative FACS plots (G) and summary data (H) of intrahepatic MICA/B expressing CD4 and CD8 T cell changes upon NKG2D blockade following
overnight HBV OLP stimulation in IHL from patients with CHB (n = 10), analyzed by Wilcoxon signed rank test. *p , 0.05, **p , 0.005, ***p , 0.001.
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50). Such selective induction and repression of particular
NKG2DL in response to different cellular stressors is consis-
tent with them having evolved non-redundant roles, despite
binding to a shared receptor (51). NKG2DL expression on a
cell can be regulated at multiple levels, including the ATM/
ATR DNA damage response driving transcription (22, 28, 50,
52) and activation of the epidermal growth factor receptor stabi-
lizing at the posttranscriptional level (24). A further possibility not
yet explored in the context of HBV infection, or liver inflammation
more generally, is the shedding of NKG2DL by cleavage, exosome
release, or secretion (22).
In terms of types of triggers of cellular stress, mitogen- or Ag-
driven activation and proliferation have been shown to induce
NKG2DL on human T cells in vitro (28), which is in line with the
increase we observed on the activated and virus-specific compo-
nent of the T cell pool. Our data suggested that metabolic stress
FIGURE 5. Impact of MICA-expressing cells on NK cell activation. Representative plots (A, gated on live CD32CD56+) of NKG2D expression on NK
cells and activation (HLA-DR) of NKG2D+NK/total NK cells from paired blood and liver samples from a CHB patient. Summary data (B) of ex vivo
staining for NKG2D on NK cells of PBMC from healthy controls (n = 23), paired PBMC and IHL from CHB (n = 23), and IHL from non-HBV infected
livers [filled circles (n = 5) IHL from healthy liver resected distant to colorectal metastases; open circles (n = 9) IHL from transplant perfusates of deceased
donor livers], analyzed by Mann–Whitney U test and Wilcoxon signed rank test. Summary data (C) of ex vivo HLA-DR on NKG2D+NK cells of PBMC
from healthy controls (n = 9), paired PBMC and IHL from CHB (n = 21), and IHL from non-HBV infected livers [filled circles (n = 5) IHL isolated from
healthy liver resected distant to colorectal metastases; open circles (n = 9) IHL from transplant perfusates], analyzed by Mann–Whitney U test and
Wilcoxon signed rank test. Correlation in (D) blood and (E) liver CHB samples (n = 20) between ex vivo MICA/B on CD4 T cells and HLA-DR on
NKG2D+NK cells, analyzed by Spearman rank correlation test. **p , 0.005, ***p , 0.001.
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within the inflamed HBV-infected liver environment could be an
additional contributor to T cell NKG2DL induction. In the HBV-
infected liver, T cells are highly dysregulated, and we have re-
cently shown that they have specific metabolic defects imposed on
them by arginase-producing myeloid cells (39). These, and other
intrahepatic cells such as Kupffer cells, can also release reactive
oxygen species (53), disrupting the local pro/antioxidant balance.
Hepatic oxidative stress has been shown to drive viral hepatitis
(54), including in a hepatitis B surface Ag transgenic mouse
model (44). Studies in patients with CHB, in particular, staining
of livers with HBV-related liver inflammation, also reveal
features of oxidative stress (45, 55, 56). The possibility that T cells
encountering their Ag in a milieu rich in oxidative stress are
predisposed to express NKG2DL was supported by our finding
that short-term in vitro exposure to hydrogen peroxide recapitu-
lated a pattern of NKG2DL induction reminiscent of that observed
in patients with CHB. This putative mechanistic link would be
strengthened if future studies find that T cells from HBV-infected
livers express additional markers of oxidative stress.
NKG2D-expressing NK cells can be sensitive to relatively
small changes in target cell MICA/B expression (23). This was
confirmed by our experiments titrating a MICA-expressing cell
line and observing that as little as 10% of MICA-expressing cells
could activate NKG2D-expressing NK cell cells. This frequency
was modeled to be reasonably representative of the situation
found within the liver sinusoids, where hepatic NK cells would
first encounter HBV-specific T cells (10, 57), a large fraction of
which expressed NKG2DL upon stimulation with their cognate
peptide. These experiments using a class-I–deficient cell line
were unable to capture the full complexity of T cell/NK cell
interactions potentially coregulating NKG2D/NKG2DL effects
in vivo. Nevertheless, they provided a controlled system to
quantify the potential contribution of NKG2DL to NK cell acti-
vation. This was further strengthened by the ex vivo correlation
observed between HLA-DR expression on NK cell and MICA/B
expression on T cells, especially within the intrahepatic com-
partment. This suggests that stress signaling from NKG2DL-
expressing intrahepatic CD4 T cells could be one factor accounting
for the ∼3-fold increase in activation of NK cells in HBV-infected
compared with healthy livers.
The NKG2D receptor on NK cells is primarily known for its
role in the recognition of transformed and infected cells; in this
study we have demonstrated its capacity to act as a sensitive de-
tector of T cell stress in the liver. Although previous studies have
shown that engagement by either cell-bound (48, 58) or soluble
(47) NKG2DL can downregulate NKG2D, we found a paradoxical
increase in NKG2D expression on intrahepatic NK cells. The
mechanism for this counterintuitive finding is the subject of on-
going studies. Virtually all intrahepatic NK cells expressed NKG2D
and were consistently more activated in the HBV-infected liver than
their circulating counterparts, or than NK cells in healthy livers.
Our finding that NKG2D blockade of liver-infiltrating lymphocytes
rescued HBV-specific and MICA/B-expressing CD4 but not CD8
T cells is in line with the fact that MICA/B was expressed at
significantly higher levels on global, activated and HBV-specific
CD4 than CD8 cells within the liver; however, it may also be
attributable to CD8 T cells possessing additional mechanisms to
protect them from NKG2D-mediated NK cell killing (7). Our
findings are underscored by previously published work showing
that NKG2D blockade rescues HBV-specific CD4 and not CD8
T cells in patients on antiviral therapy for CHB (11) and that
activated NK cells from the circulation can kill T cells that have
been activated in vitro to express NKG2DL (27–29). It was
difficult to assess the full extent of NKG2D-dependent NK cell
killing of T cells in CHB by the experimental approach we had to
use, because in vitro blockade could only rescue those T cells not
already deleted in vivo. The paradoxical preservation of some
NKG2DL-expressing T cells in the presence of NKG2D+ NK cells
is reminiscent of our previous finding of increased TRAIL+ NK
cells and TRAIL-R2+ T cells colocated within the intrahepatic
compartment (10). This could reflect the continued replacement of
deleted virus-specific T cells with newly generated populations
during persistent infection [as shown in lymphocytic choriomenin-
gitis virus (59)] or the fact that a subset of T cells may be able to
resist deletion, through for example NLCR5-induced MHC class I,
recently described to shield T cells from NK cell mediated elimi-
nation during inflammation (60). NK cells in the HBV-infected liver
also have the capacity to kill hepatocytes (20, 61), thereby con-
tributing to liver damage; the association of T cells expressing
NKG2DL with raised ALT suggests they may also promote NK
cytotoxicity toward hepatocytes. Future studies should explore
whether it is possible to manipulate the HBV-infected liver envi-
ronment to reduce NKG2DL induction on T cells, for example with
free radical scavengers, thereby potentially boosting antiviral T cells
while retuning NK cell activation and cytotoxicity.
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